<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03741257</url>
  </required_header>
  <id_info>
    <org_study_id>N-55-2018</org_study_id>
    <nct_id>NCT03741257</nct_id>
  </id_info>
  <brief_title>Comparison Between Two Concentration of Hypertonic Saline in Intestinal Obstruction Surgery</brief_title>
  <official_title>Hypertonic Saline 3% Compared to Hypertonic Saline 1.8% for Fluid Management of Intestinal Obstruction Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and Rationale :

      Perioperative fluid management is a challenging issue in surgical care especially in a
      procedure specific model. Recently hypertonic saline (HS) has the advantage of using the
      patient's own total body water by drawing interstitial space. Although it still controversial
      whether HS is associated with benefits in specific patient populations, particularly with
      respect to site of lesion and illness severity; these data provide insight into therapeutic
      modalities to curtail ileus formation.

      Objectives :

        -  Measurement of total volume of fluid infused, the need of inotropic or vasopressor to
           maintain adequate hemodynamic parameters with assessment of electrolyte disturbances and
           S.lactate

        -  The incidence rate of surgical complications; infection and anastomotic dehiscence

      Study population &amp; Sample size :

      There were no previous trials comparing the two studied groups of the current trial. We
      expected a small standardized effect size of 0.2. Based on this effect size, 25 subjects will
      be needed to elicit the difference between the two groups at an alpha level of 0.05 and power
      of 0.9 (Whitehead et al; 2016).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total volume of infused fluids</measure>
    <time_frame>24 hours</time_frame>
    <description>the total volume of fluids given to subjects intraoperatively and postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>surgical complications rate</measure>
    <time_frame>4 days</time_frame>
    <description>the rate of surgical complications i.e leakage and wound dehisence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Intestinal Obstruction Fluid Management With Hypertonic Saline</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Received Hypertonic saline 3% as resuscitation fluid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Received Hypertonic saline 1.8% as resuscitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic saline</intervention_name>
    <description>resuscitation fluid</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 20-70 years old

          -  ASA≤III

          -  BMI 25-40kg/m.

        Exclusion Criteria:

          -  Severe CVS diseases (EF&lt;50%)

          -  Severe pulmonary diseases (Pulmonary function test ≤ 50% of predicted)

          -  Neurological disorders; Psychological diseases, demyelinating lesions, Parkinsonism,
             motor or sensory disorders.

          -  Pregnancy.

          -  Severe chronic renal disease (s. Creatinine&gt; 2gm/dl or patients on dialysis).

          -  Severe hepatic impairment (Child &amp; Pugh classification class C).

          -  Acid-base and electrolytes disturbances.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rasha Behery, MD</last_name>
    <phone>+201228604556</phone>
    <email>rasha.behery.rz@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Lotfy, MD</last_name>
    <phone>+201000608905</phone>
    <email>ahmed.lotfy@kasralainy.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo University Hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Lotfy, MD</last_name>
      <phone>+201000608905</phone>
      <email>ahmed.lotfy@kasralainy.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 11, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Lotfy</investigator_full_name>
    <investigator_title>lecturer of anesthesia and intensive care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

